Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SKYEthis companySkye Bioscience, Inc.	$0.90	-0.53×	1.49×	0×	-0.44×	-40.6%	0.0%	0.0%	0.0%	-279.3%	-286.6%	-144.8%	0.01×	0.1×	0×	3.3×	0.0%	1	-41.52	2	C+
ALGSAligos Therapeutics, Inc.	$4.55	-3.8×	1.72×	42.14×	-3.45×	-97.4%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	C
CVMCEL-SCI Corporation	$1.48	-1.47×	2.34×	0×	-1.71×	-84.4%	0.0%	0.0%	0.0%	-159.2%	-97.4%	-46.0%	0.59×	0.08×	-38.23×	2.26×	0.0%	2	-38.36	2	C
INMBINmune Bio, Inc.	$1.17	-0.84×	1.76×	829.46×	-0.39×	-44.6%	100.0%	-61738.0%	-91866.0%	-195.3%	-125.7%	-57.0%	0.04×	0.52×	0×	3.55×	0.0%	1	-9.17	2	C+
PDSBPDS Biotechnology Corporation	$1.09	-1.04×	3.86×	0×	-0.86×	-89.5%	0.0%	0.0%	0.0%	-372.9%	-116.5%	-77.7%	1.83×	0.32×	-5.91×	2.98×	0.0%	2	-44.34	2	C
XFORX4 Pharmaceuticals, Inc.	$3.39	-2.14×	0.91×	4.82×	-0.43×	507.4%	82.2%	-247.4%	-225.6%	-42.5%	-32.7%	-52.4%	0.41×	2.03×	-9.79×	10.16×	0.0%	3	-1.5	2	C
Peer median	—	-1.47×	1.76×	4.82×	-0.86×	-84.4%	57.5%	-247.4%	-225.6%	-159.2%	-116.5%	-57.0%	0.41×	0.52×	-5.91×	3.55×	0.0%	2	-16.11	2	—